Showing 1381-1390 of 2656 results for "".
- EU Authorizes AstraZeneca’s COVID-19 Vaccine Amid Supply Disputehttps://modernod.com/news/eu-authorizes-astrazenecas-covid-19-vaccine-amid-supply-dispute/2478816/The European Commission on Friday granted a conditional marketing authorization to AstraZeneca and the University of Oxford’s AZD1222 for people aged 18 years and older, making it the third COVID-19 vaccine authorized in the EU, following Pfizer and BioNTech’s vaccine Comirnaty, as we
- WHO Validates Pfizer, BioNTech’s COVID-19 Vaccine for Emergency Usehttps://modernod.com/news/who-validates-pfizer-biontechs-covid-19-vaccine-for-emergency-use/2478709/The World Health Organization (WHO) said Pfizer and BioNTech’s COVID-19 vaccine BNT162b2 became the first vaccine to receive WHO validation for emergency use since the pandemic began. According to the WHO, BNT162b2 has met the agency’s “must-have” criteria for safety and e
- Japan Conducts World’s First Transplant With iPS Cells for Corneal Diseasehttps://modernod.com/news/japan-conducts-worlds-1st-transplant-with-ips-cells-for-corneal-disease/2476836/A research team from Japan’s Osaka University said Thursday that it has conducted the world’s first transplant for corneal disease using induced pluripotent stem (iPS) cells. The team conducted the surgery in July, allowing iPS corneal tissues to replace the current queuing for cornea
- Wize Pharma Announces Publication of LOA2 Data on Treatment of Moderately Severe Sjögren’s Syndrome-Related Dry Eyehttps://modernod.com/news/wize-pharma-announces-publication-of-loa2-data-on-treatment-of-moderately-severe-sjogrens-syndrome-related-dry-eye/2476200/Wize Pharma announced publication of data generated in an investigator initiated study conducted in Hungary during 2016, entitled “Treatment of Moderately Severe Sjögren’s Syndrome-Related Dry Eye without Immunomodulation: A Self-Controlled, Unmasked S
- Visual Dysfunction: An Underrecognized Symptom of Parkinson’s?https://modernod.com/news/visual-dysfunction-an-underrecognized-symptom-of-parkinsons/2477049/Visual symptoms are a potentially underrecognized and undertreated cause of reduced quality of life in Parkinson disease patients, a new study suggests, as reported in Medscape. By analyzing data from a large population health surv
- From COVID-19 to Retail Health: Fierce Healthcare’s Biggest Stories of 2020https://modernod.com/news/from-covid-19-to-retail-health-fierce-healthcares-biggest-stories-of-2020/2478689/The year 2020 was dominated by the fallout from a generational global pandemic. So perhaps it’s no surprise that COVID-19 headlines also governed much of
- NIAID Launches ACTT 2 Trial Testing Gilead’s Remdesivir Plus Eli Lilly, Incyte’s JAK Inhibitor Olumiant in COVID-19https://modernod.com/news/niaid-launches-actt-2-trial-testing-gileads-remdesivir-plus-eli-lilly-incytes-jak-inhibitor-olumiant-in-covid-19/2477741/The US National Institute of Allergy and Infectious Diseases (NIAID) said Friday that it is enrolling hospitalized adults with COVID-19 in the US to take part in a study evaluating the combination of Gilead Sciences’ remdesivir with Eli Lilly and Incyte’s JAK inhibitor Olumiant as a p
- American Academy of Optometry Announces Peter Scott as New Executive Directorhttps://modernod.com/news/american-academy-of-optometry-announces-peter-scott-as-new-executive-director/2476390/The American Academy of Optometry has announced that Peter Scott, CAE, APR, MBA will assume the position of executive director in mid-April 2019. The Academy’s outgoing Executive Director, Lois Schoenbrun, CAE, FAAO, will retire from her position at the end of April. Ms. Schoenbrun has been execu
- AOA Announces 2019 National Optometry Hall of Fame Inducteeshttps://modernod.com/news/aoa-announces-2019-national-optometry-hall-of-fame-inductees/2476443/The American Optometric Association has announced the four ODs who will be inducted into the National Optometry Hall of Fame in 2019. This year’s inductees are: Murray Fingeret, OD; Donald Jarnagin, OD; Michael Mittelman, OD; and Glen Steele, OD.
- BJO Publishes New Data on Clearside Biomedical’s Investigational Treatment Xiperehttps://modernod.com/news/bjo-publishes-new-data-on-clearside-biomedicals-investigational-treatment-xipere/2478989/New data has been published in The British Journal of Ophthalmology related to the clinical development program of Clearside Biomedical’s Xipere, an investigational treatment with a proposed indication of macular edema associated with noninfectious uveitis.